PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
INTERNAL TEMPLATE MEMORANDUM SETTLEMENT APPROVAL REQUEST
Prepared By: Calderwood & Harkness LLP 350 South Grand Avenue, 48th Floor Los Angeles, California 90071
Client: Optiwave Semiconductor Corp. ("OWS" or the "Company")
Matter: Optiwave Semiconductor Corp. v. Lumicore Technologies, Inc., Case No. 2:24-cv-00319-JRG (E.D. Tex.)
Purpose: This template memorandum is intended for use in seeking approval of any proposed settlement from the OWS Board of Directors (the "Board") and Ridgeline Capital Partners, LP ("Ridgeline"), a 55% equity holder of OWS, pursuant to the corporate governance requirements established under OWS Board Resolution No. 2024-07, adopted on March 5, 2024, and the engagement letter between Calderwood & Harkness LLP and Optiwave Semiconductor Corp. dated March 18, 2024 (the "Engagement Letter"). This memorandum is designed to provide the Board and Ridgeline with a comprehensive analysis of any proposed settlement, a comparison of the settlement to the expected value of continued litigation through trial, and counsel's recommendation as to the appropriate course of action.
NOTE: This is a blank template and standard form. All bracketed fields are placeholders to be completed when a specific settlement proposal is under consideration. Illustrative guidance text is provided in italics within each section. This template should be adapted as necessary to address the specific facts and circumstances of any proposed settlement. Counsel preparing the completed memorandum should delete all instructional text and placeholder brackets before circulating the final version to the Board.
Right-click to update Table of Contents
SECTION 1: COVER MEMORANDUM
1.1 Header Block
TO: [Insert name(s) of Board Chair and General Counsel — e.g., "Margaret S. Chen, Chair, Board of Directors; David L. Russo, Executive Vice President and General Counsel"]
CC: [Insert name(s) of PE sponsor representative(s) to receive copy, if applicable — e.g., "James R. Hartwell, Managing Director, Ridgeline Capital Partners, LP; Katherine P. Monroe, Portfolio Oversight Committee, Ridgeline Capital Partners, LP"]
FROM: [Insert name of Responsible Partner, Calderwood & Harkness LLP — e.g., "Richard E. Townsend, Partner, Calderwood & Harkness LLP"]
DATE: [Insert date of memorandum]
RE: Settlement Approval Request — Optiwave Semiconductor Corp. v. Lumicore Technologies, Inc., Case No. 2:24-cv-00319-JRG (E.D. Tex.)
PRIVILEGE DESIGNATION: This memorandum is protected by the attorney-client privilege and the work-product doctrine. It contains the legal analysis, mental impressions, conclusions, and recommendations of counsel. Do not copy, forward, or distribute this memorandum or any portion thereof without the express prior written approval of the General Counsel of Optiwave Semiconductor Corp. Receipt of this memorandum by any person not authorized to receive it does not constitute a waiver of any applicable privilege.
1.2 Executive Summary
Instruction: Provide a concise (1–2 paragraph) summary of the proposed settlement. The Executive Summary should be written so that a Board member reading only this section would understand the key terms of the proposal, the financial magnitude of the settlement, how the settlement compares to the expected value of continued litigation, and counsel's recommended course of action. Reference the litigation budget authorization and the approval thresholds established by the Board under Resolution No. 2024-07. If the proposed settlement value exceeds the threshold requiring PE sponsor approval under the Stockholders' Agreement, note that fact explicitly.
[Insert brief description of the proposed settlement terms, identifying the counterparty (Lumicore Technologies, Inc.), the primary form of consideration (e.g., lump-sum cash payment, running royalty, combination), and the key non-monetary terms (e.g., scope of license grant, dismissal with prejudice, mutual releases). Summarize the total monetary value of the settlement, including the present value of any royalty stream, and compare that value to the probability-weighted expected value of the litigation as set forth in Section 4 of this memorandum.]
[Insert total monetary consideration — specify whether the value represents a lump-sum payment, a discounted present value of a royalty stream, or a combined figure. State the total in U.S. dollars.]
[Insert recommended action — e.g., "Calderwood & Harkness recommends that the Board approve the proposed settlement," or "Calderwood & Harkness recommends that the Board reject the proposed settlement and authorize counsel to communicate a counter-proposal as described in Section 8.2," or "Calderwood & Harkness recommends that the Board defer a decision pending the outcome of the Markman hearing scheduled for [date]."]
[Insert reference to Board Resolution No. 2024-07, noting the specific approval threshold applicable to the proposed settlement (e.g., "The proposed settlement value of $[amount] exceeds the $[threshold] authorization granted to the General Counsel under Board Resolution No. 2024-07 and therefore requires affirmative approval by the Board. In addition, as the proposed settlement value exceeds $[PE threshold], approval by Ridgeline Capital Partners, LP is required under Section [X] of the Stockholders' Agreement dated [date].").]
SECTION 2: BACKGROUND AND PROCEDURAL POSTURE
2.1 Summary of the Litigation
Instruction: Provide a brief overview of the case for Board members who may not have reviewed recent litigation updates. This summary should be sufficient to orient a reader who is generally familiar with the dispute but may not recall specific details regarding the patents asserted, the theories of liability, or the damages claimed. Include all of the following elements:
Court and Case Number: [Insert court name and case number — e.g., "United States District Court for the Eastern District of Texas, Case No. 2:24-cv-00319-JRG"]
Date Complaint Filed: [Insert filing date of the original complaint — e.g., "February 12, 2024"]
Presiding Judge: [Insert name of the presiding judge — e.g., "The Honorable John R. Gilstrap, United States District Judge"]
Defendant: [Insert defendant's full legal name and any short-form reference — e.g., "Lumicore Technologies, Inc., a Delaware corporation headquartered in San Jose, California ('Lumicore' or 'Defendant')"]
Nature of Claims Asserted:
[Insert the number of patents asserted and identify each patent by number and short title. For example:]
OWS has asserted the following [number] United States patents against Lumicore in this action:
• U.S. Patent No. [X,XXX,XXX] (the "'[XXX] Patent"), entitled "[Title]," issued [date];
• U.S. Patent No. [X,XXX,XXX] (the "'[XXX] Patent"), entitled "[Title]," issued [date];
• U.S. Patent No. [X,XXX,XXX] (the "'[XXX] Patent"), entitled "[Title]," issued [date].
[Insert summary of the counts asserted in the complaint. For example:]
The operative complaint asserts the following causes of action:
• Count I: Direct infringement of the '[XXX] Patent under 35 U.S.C. § 271(a);
• Count II: Induced infringement of the '[XXX] Patent under 35 U.S.C. § 271(b);
• Count III: Contributory infringement of the '[XXX] Patent under 35 U.S.C. § 271(c);
• Count IV: Direct infringement of the '[XXX] Patent under 35 U.S.C. § 271(a);
• [Continue for each count]
• Count [X]: Willful infringement of the '[XXX] Patent, '[XXX] Patent, and '[XXX] Patent, entitling OWS to enhanced damages under 35 U.S.C. § 284.
Current Aggregate Damages Demand: [Insert the current aggregate damages demand — e.g., "OWS's current damages demand, as set forth in its preliminary infringement contentions and supporting expert analysis, is approximately $[amount], comprising lost profits of $[amount] and reasonable royalties of $[amount]. OWS also seeks enhanced damages of up to three times the damages found by the jury for willful infringement."]
Injunctive Relief Sought: [Insert description of the injunctive relief sought — e.g., "OWS has moved for, and continues to seek, a permanent injunction pursuant to 35 U.S.C. § 283, enjoining Lumicore from making, using, selling, offering to sell, or importing into the United States any products that infringe the asserted patents, including specifically Lumicore's [product name] and [product name] product lines. OWS also seeks an order requiring Lumicore to recall infringing products from its distribution channels."]
2.2 Current Procedural Status
Instruction: Describe the current procedural posture of the litigation as of the date of this memorandum. Board members should understand where the case stands relative to the overall litigation timeline and what key events remain before trial. This section should address each of the following elements:
Status of Pleadings:
[Insert current status of pleadings — e.g., "OWS filed the original complaint on [date]. Lumicore filed its Answer and Counterclaims on [date], asserting counterclaims for declaratory judgment of non-infringement, invalidity, and unenforceability with respect to each of the asserted patents. OWS filed its Answer to Counterclaims on [date]. No motions to amend are currently pending."]
Venue and Transfer Motions:
[Insert outcome of any venue motions — e.g., "Lumicore filed a motion to transfer venue to the Northern District of California under 28 U.S.C. § 1404(a) on [date]. The Court denied the motion on [date], finding that the Eastern District of Texas was a proper and convenient venue."]
Claim Construction Proceedings:
[Insert status of claim construction — e.g., "The parties exchanged proposed claim constructions on [date]. Claim construction briefs were filed on [date] (opening) and [date] (responsive). The Court has scheduled a Markman hearing for [date]. [Alternatively: The Court held a Markman hearing on [date] and issued its Claim Construction Order on [date]. The Court's constructions are [generally favorable / mixed / generally unfavorable] to OWS's infringement theories. Key constructions are discussed in Section 4.1 below.]"]
Fact discovery:
[Insert status of fact discovery — e.g., "Fact discovery opened on [date] and is currently scheduled to close on [date]. To date, OWS has produced approximately [X] documents and Lumicore has produced approximately [X] documents. OWS has completed [X] of [X] planned depositions of Lumicore fact witnesses. Lumicore has completed [X] of [X] planned depositions of OWS fact witnesses. The following depositions remain to be taken: [list key remaining depositions]."]
Expert discovery:
[Insert expert discovery timeline — e.g., "Expert reports are due on [date] (opening) and [date] (rebuttal). Expert depositions are scheduled to be completed by [date]. OWS has retained [expert name], [title/affiliation], as its technical expert on infringement, [expert name], [title/affiliation], as its damages expert, and [expert name], [title/affiliation], as its industry expert. Lumicore has identified its experts as [list if known]."]
Dispositive and Daubert Motion Deadlines:
[Insert motion deadlines — e.g., "The deadline for filing dispositive motions (including summary judgment motions) is [date]. The deadline for filing Daubert motions to exclude expert testimony is [date]. Responses are due [date], and replies are due [date]. No dispositive motions have been filed to date."]
Trial Date and Estimated Length:
[Insert trial information — e.g., "Trial is currently scheduled to begin on [date] before Judge [name] and a jury. The Court has allotted [X] days for trial, with each side receiving [X] hours of trial time. A pretrial conference is scheduled for [date]."]
Key Upcoming Deadlines Summary:
[Insert a chronological summary of the key upcoming deadlines, presented in a table format for ease of reference:]
2.3 Settlement Negotiation History
Instruction: Summarize the history of settlement discussions between the parties. This section should provide the Board with a complete chronology of all settlement-related contacts, including any pre-suit licensing outreach, mediation efforts, and any prior settlement proposals exchanged. Identify the persons involved in settlement discussions on each side, including any mediators retained. If settlement discussions are subject to Federal Rule of Evidence 408 protections, note that fact but provide the Board with the substance of the discussions for purposes of this privileged analysis.
[Insert chronology of settlement contacts. For example:]
Pre-Suit Licensing Outreach:
• On [date], OWS sent a licensing inquiry letter to Lumicore's Vice President of intellectual Property, [name], identifying the asserted patents and inviting Lumicore to discuss a licensing arrangement.
• On [date], Lumicore responded, declining to engage in licensing discussions and disputing the relevance of the identified patents to Lumicore's products.
• On [date], OWS sent a follow-up letter enclosing detailed claim charts demonstrating the applicability of the asserted patents to Lumicore's [product name] product line. Lumicore did not respond.
Post-Filing Settlement Contacts:
• On [date], following the filing of the complaint, counsel for Lumicore contacted Calderwood & Harkness to express Lumicore's interest in exploring a potential resolution. A preliminary call was held on [date] between [OWS representatives] and [Lumicore representatives].
• On [date], the parties agreed to participate in a mediation before [mediator name], [title/affiliation], who was jointly selected by the parties. The mediation session was held on [date] at [location]. The mediation did not result in a settlement at the time.
• Following the mediation, the parties exchanged the following settlement proposals:
[Insert description of any prior offers and counteroffers exchanged, identifying the date, the proposing party, and the key terms of each proposal. For example:]
• [Date] — Lumicore proposed a lump-sum payment of $[amount] in exchange for a worldwide, non-exclusive license to the asserted patents and mutual releases. OWS rejected this proposal as materially below the expected value of the litigation.
• [Date] — OWS counter-proposed a lump-sum payment of $[amount] plus a running royalty of [X]% of net sales of licensed products for a period of [X] years, together with a broad patent license and mutual releases. Lumicore rejected this proposal.
• [Date] — Lumicore submitted a revised proposal of $[amount] lump sum plus a running royalty of [X]% for [X] years. This is the proposal currently under consideration and the subject of this memorandum.
[Insert identification of mediator, if applicable — e.g., "The parties retained [mediator name], a former United States Magistrate Judge and practicing mediator with [firm name], to serve as mediator. The mediator remains engaged and has communicated the current proposal to both parties. The mediator has indicated that [his/her] assessment of the case is [insert, if applicable]."]
SECTION 3: PROPOSED SETTLEMENT TERMS
This section sets forth in detail the material terms of the proposed settlement currently under consideration. Each subsection addresses a distinct category of settlement terms. Counsel preparing the final memorandum should ensure that every material term of the proposed settlement is addressed. If a term sheet or draft settlement agreement has been exchanged, it should be attached as Attachment A and cross-referenced throughout this section.
3.1 Monetary Consideration
Instruction: Set forth in detail all monetary components of the proposed settlement, including any lump-sum payments, installment arrangements, royalty streams, minimum payments, and any other forms of monetary consideration. Where the settlement involves a royalty stream or other form of deferred consideration, include a present-value analysis using an appropriate discount rate.
Lump-Sum Payment: [Insert lump-sum payment amount, if any — e.g., "$[X] million, payable within [X] business days of the Effective Date of the Settlement Agreement"]
Payment Schedule / Installment Terms: [Insert payment schedule, if any — e.g., "Payable in [X] equal installments of $[amount] each, due on [dates], with interest accruing at [rate]% per annum on any unpaid balance"]
Prospective Royalty:
• Royalty Rate and Base: [Insert royalty rate and base — e.g., "[X]% of Net Sales of Licensed Products, where 'Net Sales' is defined as gross revenue less returns, allowances, shipping charges, and taxes, consistent with the definition used in the proposed Settlement Agreement at Section [X]"]
• Royalty Structure: [Specify whether the royalty is a running royalty on net sales, a per-unit fee (e.g., "$[X] per unit sold"), or another structure]
• Duration of Royalty Period: [Insert duration — e.g., "The royalty obligation continues for the remaining life of the longest-lived asserted patent, currently estimated to expire on [date]" or "for a fixed period of [X] years from the Effective Date"]
• Minimum Annual Royalty: [Insert any minimum annual royalty or guaranteed minimum payment — e.g., "Lumicore guarantees a minimum annual royalty payment of $[amount] per calendar year during the royalty period, payable regardless of actual sales volume"]
• Upfront License Fee / Signing Payment: [Insert any upfront license fee or signing payment separate from the lump-sum settlement payment — e.g., "In addition to the lump-sum settlement payment, Lumicore will pay a non-refundable license initiation fee of $[amount] upon execution of the Settlement Agreement"]
Total Present Value of Settlement:
[Insert total present value of the proposed settlement consideration — e.g., "Based on a discounted cash flow analysis using a discount rate of [X]% and projected Licensed Product sales as estimated by [OWS's financial analyst / damages expert], the total present value of the proposed settlement is approximately $[amount]. This figure comprises the lump-sum payment of $[amount] plus the discounted present value of the royalty stream of approximately $[amount]. The DCF analysis and underlying assumptions are set forth in Attachment B."]
Currency and Payment Mechanics: [Insert currency denomination and any specified wire instructions or payment mechanics — e.g., "All payments are denominated in United States Dollars and are to be made by wire transfer to an account designated by OWS."]
3.2 License Grant
Instruction: Describe the scope of any patent license included in the settlement. The license grant is often the most commercially significant term of a patent settlement and should be described with precision. Particular attention should be paid to whether the license extends beyond the asserted patents to include other patents in the portfolio, whether it covers future products, and whether it includes sublicense rights.
Licensed Patents: [Insert identification of licensed patents — e.g., "The license covers (a) the asserted patents (U.S. Patent Nos. [X,XXX,XXX], [X,XXX,XXX], and [X,XXX,XXX]) and all continuations, continuations-in-part, divisionals, reissues, and reexaminations thereof, or (b) [alternatively] the license is limited to the three asserted patents only, with no rights under any other OWS patents." Specify whether the license extends to any broader portfolio of OWS patents beyond the asserted patents.]
Licensed Products: [Insert identification of licensed products — e.g., "The license covers (a) the Accused Products identified in OWS's infringement contentions ([product names/model numbers]), or (b) [alternatively] all semiconductor products manufactured or sold by Lumicore during the license term, regardless of whether they were accused in this litigation." Specify whether the license extends to next-generation products or successor products that may incorporate similar technology.]
Field of Use: [Insert any field-of-use limitation — e.g., "The license is limited to the manufacture, use, sale, offer to sell, and importation of semiconductor devices for use in [specific application or industry]" or "The license is unrestricted as to field of use."]
Territorial Scope: [Insert territorial scope — e.g., "Worldwide" or "Limited to the United States and its territories"]
Exclusivity: [Insert whether the license is exclusive or non-exclusive — e.g., "The license is non-exclusive." Note: If the proposed license is exclusive, counsel should separately analyze the implications for OWS's ability to enforce the licensed patents against third parties and the impact on OWS's licensing program.]
Sublicense Rights: [Insert sublicense rights, if any — e.g., "Lumicore has no right to sublicense the Licensed Patents to any third party" or "Lumicore may grant sublicenses to its direct customers solely for the use and resale of Licensed Products purchased from Lumicore."]
Term and Renewal: [Insert term of the license — e.g., "The license term is coextensive with the remaining life of the longest-lived Licensed Patent" or "The license is for a fixed term of [X] years, with an option to renew for successive [X]-year periods upon payment of a renewal fee of $[amount]."]
Most-Favored-Licensee Provisions: [Insert any MFN provisions — e.g., "The Settlement Agreement does not include a most-favored-licensee clause" or "The Settlement Agreement provides that if OWS grants a license to any third party on terms materially more favorable than those granted to Lumicore (on a per-unit or percentage-of-net-sales basis, as applicable), OWS will offer Lumicore the benefit of such more favorable terms, subject to [specified exceptions]."]
3.3 Injunctive / Conduct Relief
Instruction: Describe any non-monetary relief included in the settlement. This section should address any agreed-upon product restrictions, design-around commitments, sunset provisions for existing customer relationships, and any ongoing reporting or compliance obligations.
Agreed Injunction or Product Restrictions: [Insert description of any agreed injunction, product withdrawal, or cessation of sales — e.g., "The proposed settlement does not include any injunctive relief or product restrictions; Lumicore will be licensed to continue manufacturing and selling all Licensed Products" or "Lumicore agrees to cease sales of [specific product] within [X] days of the Effective Date and to discontinue all marketing and promotion of such product."]
Sunset Period: [Insert any sunset or wind-down period — e.g., "Lumicore shall have a [X]-month sunset period during which it may fulfill existing contractual obligations to customers for delivery of [specific product], provided that Lumicore pays the applicable royalty on all such sales during the sunset period."]
Design-Around Commitments: [Insert any design-around commitments or restrictions on future product design — e.g., "Lumicore commits to implementing a redesign of [specific component/feature] in its [product name] product line within [X] months of the Effective Date to avoid infringement of the asserted claims. OWS retains the right to review the redesigned product for compliance."]
Reporting and Audit Obligations: [Insert any ongoing reporting or audit obligations — e.g., "Lumicore shall provide quarterly royalty reports within [X] days of the end of each calendar quarter, setting forth the quantity and Net Sales of Licensed Products. OWS shall have the right to audit Lumicore's books and records related to Licensed Product sales no more than once per calendar year, at OWS's expense, through an independent certified public accountant. If any audit reveals an underpayment of more than [X]%, Lumicore shall bear the cost of the audit and pay the shortfall plus interest at [X]% per annum."]
3.4 Releases and Covenants
Instruction: Describe the scope of the mutual releases and any covenants not to sue included in the proposed settlement. This section is critically important because the scope of releases directly affects OWS's ability to bring future claims against Lumicore and may have implications for OWS's patent enforcement program more broadly.
Scope of Mutual Release:
[Insert scope of mutual release — e.g., "The proposed settlement includes mutual releases of all claims, counterclaims, demands, and causes of action arising out of or related to the asserted patents and the Accused Products that have accrued as of the Effective Date. The release covers claims for patent infringement, declaratory judgment of non-infringement, invalidity, and unenforceability, as well as any related claims for unfair competition, trade secret misappropriation, or tortious interference that were or could have been asserted in the litigation." Specify whether the release extends only to the asserted patents or includes all intellectual property owned by either party. Specify whether the release covers past, present, and future claims.]
Covenant Not to Sue:
[Insert covenant not to sue provisions — e.g., "OWS covenants not to sue Lumicore for infringement of the Licensed Patents with respect to Licensed Products during the term of the license. The covenant extends to [specify patent families covered]. The covenant does not extend to [specify any exclusions — e.g., patents acquired after the Effective Date, patents not in the Licensed Patent families]."]
Carve-Outs and Reserved Claims:
[Insert any carve-outs or reserved claims — e.g., "The release expressly excludes (a) any claims arising under patents issued after the Effective Date that are not continuations or divisionals of the Licensed Patents, (b) any claims arising from Lumicore's breach of the Settlement Agreement, and (c) any claims related to Lumicore's activities outside the scope of the license grant."]
Handling of Counterclaims:
[Insert treatment of counterclaims — e.g., "Lumicore's counterclaims for declaratory judgment of non-infringement, invalidity, and unenforceability will be dismissed with prejudice simultaneously with the dismissal of OWS's complaint. Any remaining counterclaims [specify] will be released under the mutual release."]
3.5 Dismissal Terms
Instruction: Specify the form of dismissal contemplated by the proposed settlement. The distinction between dismissal with prejudice and without prejudice has significant legal consequences and should be clearly stated.
Form of Dismissal: [Insert whether the dismissal is with prejudice or without prejudice — e.g., "The parties will file a joint stipulation of dismissal with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii), dismissing all claims and counterclaims with prejudice, with each party bearing its own attorneys' fees and costs" or "The parties will file a stipulated consent judgment incorporating the agreed-upon terms."]
Stipulated Dismissal vs. Consent Judgment: [Insert whether the parties contemplate a stipulated voluntary dismissal or a consent judgment entered by the Court — e.g., "The proposed settlement contemplates a stipulated dismissal rather than a consent judgment. No judgment will be entered by the Court, and the settlement terms will be embodied solely in the private Settlement Agreement."]
Retention of Jurisdiction: [Insert any provisions regarding the Court's retention of jurisdiction — e.g., "The stipulation of dismissal will provide that the Court retains jurisdiction solely for the purpose of enforcing the terms of the Settlement Agreement" or "The stipulation of dismissal will not include any retention of jurisdiction. Any disputes arising under the Settlement Agreement will be resolved through the dispute resolution mechanism set forth in the Settlement Agreement (see Section 3.8 below)."]
3.6 Confidentiality and Non-Disclosure
Instruction: Describe any confidentiality provisions applicable to the settlement itself. Settlement confidentiality is often an important term for both parties and may affect OWS's ability to reference the settlement in future licensing negotiations or litigation.
Confidentiality of Settlement Amount: [Insert whether the settlement amount is confidential — e.g., "The specific monetary terms of the settlement, including the lump-sum payment amount and royalty rate, are designated as Confidential Information under the Settlement Agreement and may not be disclosed to any third party without the prior written consent of both parties, except as required by law, regulation, or legal process."]
Confidentiality of Settlement Existence: [Insert whether the existence of the settlement is confidential — e.g., "The existence of the settlement may be disclosed by either party. However, neither party may disclose the specific terms without the other party's consent" or "Both the existence and the terms of the settlement are confidential."]
Public Announcement Obligations: [Insert any press release or public announcement provisions — e.g., "The parties will issue a mutually agreed joint press release announcing the resolution of the litigation. The press release will state that the parties have resolved the litigation on mutually acceptable terms but will not disclose specific financial terms" or "Neither party shall issue any press release or public statement regarding the settlement without the prior written consent of the other party."]
SEC Disclosure Obligations: [Insert any applicable SEC disclosure obligations — e.g., "Lumicore, as a publicly traded company (NASDAQ: LCOR), may be required to disclose material terms of the settlement in its periodic filings with the Securities and Exchange Commission (Form 8-K, Form 10-Q, or Form 10-K). The Settlement Agreement acknowledges this obligation and provides that any such disclosure shall be limited to the minimum required by applicable law and regulation. Lumicore will provide OWS with advance notice and a draft of any proposed disclosure for review and comment." If OWS is also a public reporting company or has disclosure obligations to investors or lenders, address those as well.]
3.7 Admission of Liability
Instruction: Specify whether the settlement includes any admission or denial of liability by either party. Most patent settlements are structured on a no-admission, no-denial basis, but this should be confirmed and documented.
No-Admission, No-Denial: [Insert whether the settlement is on a no-admission, no-denial basis — e.g., "The Settlement Agreement provides that the settlement is entered into solely for the purpose of compromising disputed claims and avoiding the cost and uncertainty of further litigation. Neither party admits the validity or enforceability of any patent, the infringement or non-infringement of any patent, or any fault, liability, or wrongdoing of any kind. The Settlement Agreement expressly states that it shall not be construed as an admission, concession, or indication of any party's views regarding the merits of any claim or defense."]
Specific Non-Admission Language: [Insert any specific language regarding non-admission of infringement, validity, or enforceability — e.g., "The Settlement Agreement includes the following specific non-admission language: 'Lumicore does not admit that any of its products infringe any valid and enforceable claim of any of the Asserted Patents. OWS does not admit that any of the Asserted Patents is invalid or unenforceable.'"]
3.8 Other Material Terms
Instruction: Describe any additional material terms of the proposed settlement not covered in the preceding subsections. This section serves as a catch-all to ensure that all significant provisions are brought to the Board's attention.
Cross-License Provisions: [Insert any cross-license provisions — e.g., "As part of the settlement, Lumicore will grant OWS a non-exclusive, royalty-free license to [specific Lumicore patents], limited to [scope]" or "The proposed settlement does not include any cross-license from Lumicore."]
Standstill or Non-Compete Provisions: [Insert any standstill or non-compete provisions — e.g., "The proposed settlement does not include any standstill or non-compete provisions" or "Lumicore agrees to a [X]-year standstill period during which it will not file any action challenging the validity or enforceability of the Licensed Patents."]
Technology Cooperation Arrangements: [Insert any technology cooperation, supply, or partnership arrangements — e.g., "The proposed settlement does not include any technology cooperation or supply arrangements" or "As part of the settlement, the parties have agreed to enter into a separate Technology Cooperation Agreement under which [describe terms]."]
Representations and Warranties: [Insert any representations and warranties by either party — e.g., "Each party represents and warrants that it has the corporate authority to enter into the Settlement Agreement, that the execution and performance of the Settlement Agreement will not violate any other agreement to which it is a party, and that the Licensed Patents (as to OWS) are not subject to any liens, encumbrances, or prior exclusive licenses that would prevent the grant of the license contemplated by the Settlement Agreement."]
Governing Law and Dispute Resolution: [Insert the governing law and dispute resolution mechanism for the Settlement Agreement — e.g., "The Settlement Agreement will be governed by the laws of the State of Delaware, without regard to conflict-of-laws principles. Any disputes arising under or relating to the Settlement Agreement will be resolved by binding arbitration administered by JAMS in Los Angeles, California, in accordance with the JAMS Comprehensive Arbitration Rules, before a single arbitrator mutually agreed upon by the parties."]
Conditions Precedent to Closing: [Insert any conditions precedent — e.g., "The Settlement Agreement is subject to the following conditions precedent: (a) approval by the OWS Board of Directors, (b) approval by Ridgeline Capital Partners, LP, as required under the Stockholders' Agreement, (c) [any regulatory clearance required], and (d) execution and delivery of the final Settlement Agreement by both parties within [X] business days of satisfaction of all other conditions."]
SECTION 4: COMPARISON TO EXPECTED TRIAL OUTCOME
This section provides a detailed comparison of the proposed settlement to the expected value of continued litigation through trial. The purpose of this analysis is to enable the Board to make an informed decision by weighing the certainty and value of the proposed settlement against the probability-weighted expected value and inherent uncertainty of a trial outcome. This analysis should be read in conjunction with the Decision-Tree / Expected-Value Analysis attached as Attachment B and the Damages Summary attached as Attachment D.
4.1 Liability Assessment
Instruction: Provide counsel's assessment of the probability of prevailing on the merits at trial. This assessment should address each major liability issue, including infringement (literal and under the doctrine of equivalents), invalidity, unenforceability, and willfulness. The assessment should be informed by the current state of discovery, the claim construction posture, and counsel's evaluation of the strength of the evidence developed to date.
Overall Probability of Prevailing:
[Insert counsel's overall assessment of the probability of prevailing on at least one asserted patent — express as a percentage range. For example: "Based on our current assessment of the evidence, the claim construction posture, and the strength of Lumicore's defenses, we estimate that OWS has a [X]% to [X]% probability of prevailing on at least one asserted patent at trial."]
Infringement Assessment by Patent:
[Insert a patent-by-patent assessment of infringement strength, referencing the current claim construction posture. For each asserted patent, address:]
[Patent 1 — e.g., the '[XXX] Patent]:
• Literal Infringement: [Insert assessment of literal infringement — e.g., "We assess the probability of establishing literal infringement of at least one claim of the '[XXX] Patent at [X]%. The key claim limitation at issue is [describe limitation]. The evidence developed to date, including Lumicore's source code and product testing results, [supports / raises questions about] a finding of literal infringement. The Court's construction of the term '[claim term]' in its Markman order [favorably / adversely] affects our literal infringement theory."]
• Doctrine of Equivalents: [Insert assessment of DOE claims — e.g., "If the literal infringement theory is unsuccessful, OWS has a fallback argument under the doctrine of equivalents with respect to [describe equivalent]. However, there is a risk of prosecution history estoppel arising from the [describe amendment or argument made during prosecution] that may limit the range of equivalents available. We assess the probability of prevailing under the doctrine of equivalents at [X]%."]
[Patent 2 — e.g., the '[XXX] Patent]:
• Literal Infringement: [Insert assessment]
• Doctrine of Equivalents: [Insert assessment]
[Patent 3 — e.g., the '[XXX] Patent]:
• Literal Infringement: [Insert assessment]
• Doctrine of Equivalents: [Insert assessment]
Invalidity Defenses:
[Insert assessment of Lumicore's invalidity defenses for each asserted patent — e.g., "Lumicore has asserted invalidity defenses under 35 U.S.C. §§ 102 and 103. The strongest prior art references identified to date are [references]. Our assessment of the probability that Lumicore will successfully invalidate each asserted patent is as follows: [Patent 1]: [X]%; [Patent 2]: [X]%; [Patent 3]: [X]%. Secondary considerations of non-obviousness, including commercial success of OWS's products embodying the patented technology and evidence of long-felt but unmet need, [support / may not fully overcome] a defense of obviousness."]
Unenforceability / Inequitable Conduct:
[Insert assessment — e.g., "Lumicore has asserted a defense of unenforceability based on alleged inequitable conduct during the prosecution of the '[XXX] Patent. Specifically, Lumicore alleges that OWS's prosecuting attorney failed to disclose [reference] to the Patent Office. We assess the probability that Lumicore will prevail on this defense at [X]%. The Brightmoor & Co. 'but-for' materiality standard is difficult to satisfy, and the evidence of specific intent to deceive is [weak / moderate / strong]."]
Willful Infringement:
[Insert assessment — e.g., "OWS has asserted a claim of willful infringement under 35 U.S.C. § 284 and Halo Electronics, Inc. v. Pulse Electronics, Inc., 579 U.S. 93 (2016). The evidence of willfulness includes [describe — e.g., pre-suit knowledge of the patents, failure to obtain opinion of counsel, copying of OWS's technology]. We assess the probability of a finding of willful infringement at [X]%, and if willfulness is found, we estimate a damages enhancement multiplier in the range of [X]x to [X]x."]
Induced and Contributory Infringement:
[Insert assessment — e.g., "OWS has asserted claims of induced infringement under § 271(b) and contributory infringement under § 271(c). The induced infringement claim is based on Lumicore's [describe conduct — e.g., provision of instruction manuals, technical support, and promotional materials encouraging customers to use the accused products in an infringing manner]. The contributory infringement claim is based on [describe — e.g., the sale of a component that has no substantial non-infringing use]. We assess the probability of prevailing on induced infringement at [X]% and on contributory infringement at [X]%."]
4.2 Damages Assessment
Instruction: Summarize the range of potential damages recoverable at trial under each damages theory asserted by OWS. This analysis should cross-reference the preliminary analysis prepared by OWS's damages expert, which is summarized in Attachment D.
Lost Profits:
[Insert lost profits estimate — e.g., "OWS's damages expert, [name], has estimated OWS's lost profits at approximately $[amount], based on the Panduit four-factor test. Key assumptions underlying this estimate include: (a) demand for the patented product — [describe]; (b) absence of acceptable non-infringing alternatives — [describe]; (c) OWS's manufacturing and marketing capability — [describe]; and (d) the amount of profit OWS would have made — gross margin of [X]% and estimated market share displacement of [X]%. The lost profits estimate is [well-supported / subject to challenge] based on the current record."]
Reasonable Royalty:
[Insert reasonable royalty estimate — e.g., "As an alternative to lost profits (and for any infringing sales not covered by the lost-profits analysis), OWS's damages expert has calculated a reasonable royalty of $[amount], based on a hypothetical negotiation analysis under Georgia-Pacific Corp. v. United States Plywood Corp. Key assumptions include a royalty rate of [X]% applied to a royalty base of $[amount] (representing [the price of the accused product / the smallest salable patent-practicing unit / the entire product, under the EMVR]). The royalty rate is supported by comparable license agreements, including [identify key comparable licenses]."]
Enhanced Damages:
[Insert enhanced damages estimate — e.g., "If the jury finds willful infringement, the Court has discretion to enhance damages by up to three times the amount found by the jury. Based on the Halo factors, we estimate an enhancement multiplier of [X]x, yielding enhanced damages of approximately $[amount] on top of the base damages award."]
Total Damages Range:
[Insert total damages range across scenarios:]
Apportionment and EMVR Risks:
[Insert analysis of apportionment risks — e.g., "There is a risk that the Court or jury may require apportionment of the royalty base to reflect only the value attributable to the patented feature, rather than applying the royalty to the entire market value of the accused product. Lumicore will argue that the patented feature accounts for only [X]% of the value of the accused product. If the Court accepts this argument, the reasonable royalty could be reduced to approximately $[amount]."]
Daubert Risks:
[Insert assessment of Daubert challenges — e.g., "Lumicore is expected to file a Daubert motion seeking to exclude or limit the testimony of OWS's damages expert on the following grounds: [describe — e.g., unreliable methodology, failure to apportion, improper use of entire market value rule]. We assess the risk of partial or full exclusion of damages expert testimony at [X]%. If the expert's lost-profits opinion is excluded, recovery would be limited to the reasonable-royalty theory."]
4.3 Injunction Assessment
Instruction: Assess the likelihood of obtaining a permanent injunction following a favorable trial verdict and evaluate the practical commercial value of injunctive relief.
Cascade Holdings Factor Analysis:
[Insert assessment of each of the four Northgate Group v. MercExchange, L.L.C. factors:]
1. Irreparable Harm: [Insert assessment — e.g., "OWS competes directly with Lumicore in the [market segment]. Lumicore's continued sale of infringing products has caused and will continue to cause irreparable harm to OWS in the form of [lost sales, price erosion, loss of customer relationships, damage to brand reputation]. OWS can present evidence of [specific irreparable harm]. We assess this factor as [favoring / disfavoring] injunctive relief."]
2. Inadequacy of Legal Remedies: [Insert assessment — e.g., "While monetary damages may partially compensate OWS for past infringement, ongoing damages are difficult to calculate and may not adequately compensate OWS for the erosion of its competitive position. We assess this factor as [favoring / disfavoring] injunctive relief."]
3. Balance of Hardships: [Insert assessment — e.g., "An injunction would require Lumicore to cease sales of its [product name] product line, which accounts for approximately [X]% of Lumicore's annual revenue. Lumicore would need an estimated [X] months to develop a non-infringing redesign. While the hardship to Lumicore is significant, Lumicore had notice of OWS's patents and chose to proceed with its infringing design. We assess this factor as [favoring / slightly favoring / slightly disfavoring / disfavoring] injunctive relief."]
4. Public Interest: [Insert assessment — e.g., "The public interest in enforcing valid patent rights and encouraging innovation generally favors injunctive relief. There are no significant health, safety, or public welfare concerns that would counsel against an injunction. We assess this factor as [favoring / neutral] on injunctive relief."]
Overall Injunction Probability: [Insert overall probability — e.g., "On balance, we assess the probability of obtaining a permanent injunction at [X]%."]
Practical Value of Injunction:
[Insert estimated impact on Lumicore — e.g., "If an injunction is granted, Lumicore would be required to cease sales of its [product name] and [product name] product lines, which together account for an estimated $[amount] in annual revenue (approximately [X]% of Lumicore's total revenue). Lumicore has estimated that it would require approximately [X] months and $[amount] to develop a non-infringing redesign."]
[Insert estimated value of injunction to OWS — e.g., "An injunction would provide OWS with significant competitive leverage in the [market segment], as Lumicore would be unable to supply its customers during the redesign period. OWS estimates that it could capture approximately $[amount] in additional sales during a [X]-month period of Lumicore market absence. Additionally, the threat of an injunction provides significant leverage in licensing negotiations with other potential infringers."]
4.4 Decision-Tree / Expected-Value Analysis
Instruction: Present a quantitative expected-value analysis using a decision-tree methodology. The decision tree should assign probabilities to key litigation events — including claim construction outcomes, summary judgment, trial liability, damages findings, and post-trial motions — and calculate a probability-weighted expected recovery. The detailed spreadsheet model should be attached as Attachment B; this section should summarize the key inputs and outputs.
Key Probability Inputs:
Damages Range Inputs (If Liability Established):
Probability-Weighted Expected Value of Trial Outcome:
[Insert the probability-weighted expected value — e.g., "Based on the decision-tree analysis, the probability-weighted expected value of the trial outcome is approximately $[amount]. This figure represents the weighted average of all possible outcomes, taking into account the probabilities of success at each stage of the litigation and the range of potential damages awards."]